More on Hospital Price Transparency

The Centers for Medicare & Medicaid Services (CMS) recently issued an update on its hospital price transparency enforcement efforts. This update is part of the agency's larger goal to increase transparency and empower consumers to make informed healthcare decisions. Under the new rule, hospitals that fail to comply with the transparency requirements will face penalties of up to $300 per day, and the CMS will also publicly disclose the names of non-compliant hospitals. This move is a significant step towards holding hospitals accountable for providing accurate and easily accessible pricing information to their patients.

The CMS's update is a much-needed move towards transparency in the healthcare industry. It's no secret that medical bills are often complicated and difficult to understand, leaving many patients feeling helpless and vulnerable. By mandating that hospitals provide clear pricing information, patients will have the tools they need to make informed decisions about their healthcare. This will enable them to better plan and budget for medical procedures, avoiding the surprise bills that often come with hidden fees and unclear pricing.

However, it's important to note that the rule only applies to hospitals, and not other healthcare providers like doctors or clinics. To truly empower patients and increase transparency, these other providers should also be required to provide clear pricing information. Additionally, while the penalties for non-compliance are significant, it remains to be seen if they will be enough to incentivize hospitals to comply. The CMS will need to continue to monitor compliance closely and ensure that hospitals are following the guidelines.

CMS's update on hospital price transparency enforcement is a significant step towards empowering patients and increasing transparency in the healthcare industry. By holding hospitals accountable for providing clear pricing information, patients will be better equipped to make informed decisions about their healthcare.

Comments

Selecting Therapeutic Alternatives: A Critical Perspective for Drug Manufacturers

The Inflation Reduction Act (IRA) of 2022 instructed the Centers for Medicare and Medicaid Services (CMS) to initiate drug price negotiations with manufacturers for the first time. A key component of these negotiations involves considering factors like the drug's benefits and costs to establish a "lowest maximum fair price." (MFP) For drug manufacturers, CMS’s process for making comparisons of therapeutic alternative(s) to determine the MFP raises a number of crucial questions. The IRA's guidance suggests that CMS will initially compare drugs within the same class as the negotiated drug to determine a starting point for pricing. For drug manufacturers, this approach raises concerns regarding price competition within drug classes. As new drugs are often priced in line with preexisting brand-name drugs in the same class, the negotiation process may result in downward pressure on prices for all drugs in the class. This could significantly affect the revenue and profitabi...

TCET Pathway Could Accelerate Access to Innovating Technologies

The Centers for Medicare & Medicaid Services (CMS) proposed the Transitional Coverage for Emerging Technologies (TCET) pathway to enable quicker coverage decisions for breakthrough devices needing accelerated regulatory review. As described in JAMA Health Forum, TCET allows tailored oversight based on an innovation’s specific benefits and risks. TCET focuses on FDA Breakthrough-designated devices for serious conditions supported by limited clinical data for market authorization. By facilitating transitional coverage, TCET aims to help make cutting-edge technologies accessible to patients while additional real-world evidence is gathered to meet CMS’ “reasonable and necessary” standard. For developers to optimize TCET’s streamlined approach they should be sure to: - Pursue FDA Breakthrough designation when criteria are met. This opens the TCET pathway. - Engage CMS early on study designs and evidence needs. Incorporate draft guidance on endpoints and real-world data....

Bridging the Gap: The Long Road from FDA Approval to Medicare Coverage

A new study published in JAMA Health Forum reveals that the road to Medicare coverage for novel medical technologies is a long and winding one. Researchers found that only 44% of innovative devices and diagnostics approved by the FDA from 2016-2019 had even “nominal” Medicare coverage by 2022. This data highlights major hurdles in the system that delay patient access to beneficial emerging technologies. About the Research The study examined 281 novel products cleared through the FDA from 2016-2019 via the high-risk premarket approval, de novo, and breakthrough 510(k) pathways. These included things like groundbreaking diagnostic tests, implantable devices, and other innovative treatment technologies. The goal was to measure how long it took to establish national or regional Medicare coverage policies for these newly approved products. This is important because Medicare coverage is required before hospitals, physicians and patients can reliably access new technologies. Key Findings The ...

The Health Policy War Room

Search This Blog